49448822 Pharmaceutical Industries Ppt

8/4/2019 49448822 Pharmaceutical Industries Ppt

http://slidepdf.com/reader/full/49448822-pharmaceutical-industries-ppt 1/13

Pharmaceutical

Industry

Submitted by- ankit mishra



1. Introduction

2. About indian pharma industries

3. Growth of pharma industries

4. Key players

5. Market share

6. Key products

7. Impact on G.D.P.

8. S.W.O.T.analysis

9. Conclusion



INTRODUCTION

Pharmaceutical Industry in India is one of the largest

and most advanced among the developing countries

The Indian pharmaceutical industry has come a long

way from waiting for imports of bulk drugs from

global players to breaking new grounds in medical

research worldwide.



I NDIAN PHARMACEUTICAL I NDUSTRY

IPI is ranked 4th in volume terms and 11th in value

terms globally.

Around 70% of the country's demand for bulk drugs,

drug intermediates, pharmaceutical formulations,chemicals, tablets, capsules, orals and vaccines is met by

IPI.

The Pharmaceutical industry in India is fragmented

with over 3,000 small/medium sized generic

pharmaceutical manufacturers.



GROWTH OF THE INDUSTRY

Worth of the pharma industry ² $ 6billion

Accounts for - 1% of the world'spharma industry in value terms and8% in volume terms. .

Revenues generated - US$ 7.6 bn

and have grown at an average rate of 10% over last f ive years



K EY PRODUCTS

Medicines

Medical equipments

Surgical goods

Operation accessories

I.V.f luids

Injections



Ranbaxy*

Dr. Reddy's

Cipla

Lupin

Nicholas PiramalSun

Pharmaceuticals

GSK

Cadila

Healthcare

Aurobindo

Wockhardt*

Key players in pharmaceutical industries



MARKET SHARE

55%33%

9%

3%

Sales

1st Qtr 2nd Qtr 3rd Qtr 4th Qtr

IndianTraditionalMedicineMarketSize, 2009

(USD m)

Ayurveda-55%

Homeopathy-33%

Unani-9%

Biochemic-3%

Indian TraditionalMedicine System(ISM) -2009

� ISM market for

products in India in2006 ² USD 400m, grew at 8%

� Over 82% of it - Ayurveda,



R OLE OF PHARMACEUTICAL I NDUSTRY IN

I NDIA S GDP

It ranks 4th in the world, pertaining to the volume of sales

The estimated worth of the Indian Pharmaceutical Industry is US$ 6 billion

The growth rate of the industry is 13% per year

The current revenues are estimated at US$5.5 billion

and it is expected to grow at a compounded annual growth rate of 19% and touch US$25 billion in

revenue by 2015.



Strengths :-

1.Cost Competitiveness

2 Developed Industry with Strong

Manufacturing Base3.Well Established R&D infrastructure

4. Access to pool of highly trained

scientists,

Opportunities :-

1. Significant export potential.

2. Marketing alliances for MNC products in

domestic market and international market.3.Contract manufacturing arrangements with

MNCs

Weaknesses:-

1. Low investments in innovative

R&D.

2. Lack of resources to compete with

MNCs for New Drug Discovery &

Research3. Lack of strong linkages between

industry and academia.

Threats :-

1.Product patent regime poses serious

challenge to domestic industry unless it invests

in research and development

2. R&D efforts of Indian pharmaceutical

companies hampered by lack of enablingregulatory requirement

3. Export effort hampered by procedural

hurdles in India as well as non-tariff barriers

imposed abroad.



F UTURE OF I NDIAN PHARMA INDUSTRY

The key to survival would be the exponential growth of

R&D expenditure. Indian companies need product

patent protection to encourage research in developing

inexpensive drugs that suit the Indian disease profile.The obligations imposed on India are going to have a

significant impact on India·s successful bulk and

formulation-oriented pharmaceutical industry. Indian

companies could focus on producing patented drugs under license from foreign companies or generating

revenues from producing generic drugs.



CONCLUSION

Pharma industry being a growth industry

Unaff ected by the business cycle

As per the present growth rate, the IndianPharma Industry is expected to be a US$ 25

billion industry by the year 2015 India has

competitive strength in research services

availability of low cost skilled doctors andscientists

large patient population with diverse diseasecharacteristics

adherence to international quality standards

VLSS agencies recommends investment in thisindustry to be a wise decision.

49448822 Pharmaceutical Industries Ppt

Documents

Transcript of 49448822 Pharmaceutical Industries Ppt